uring a regulatory inspection, an inspector or auditor may review a technically complete pharmacovigilance case only to find that the narrative leaves them unclear about what actually happened to the patient, how the case evolved, and how the company reached its safety assessment.

A pharmacovigilance case can be technically complete and still fail the real-world test of inspection readiness if the narrative does not clearly explain what happened, how the case evolved, and how the safety conclusion was reached. The gap is easy to miss in busy safety operations, but during inspection, it can quickly become visible. That makes narrative quality more than a writing task. It becomes a matter of inspection readiness, clinical clarity, and consistency across the workflow.

In an exploratory industry pulse survey of 10 pharmacovigilance professionals involved in case processing, narrative writing, quality review, and medical assessment, several themes emerged consistently: Narrative variability across similar cases is common, quality control (QC) often focuses on technical completeness, and inconsistencies frequently arise during workflow handoffs. While the sample was small and not intended to be statistically representative, the responses highlight an operational issue many safety teams recognize: A case can meet technical requirements and still be difficult to defend if the clinical story is unclear.

While exploratory, the responses were directionally consistent across case processing, quality review, narrative writing, and medical assessment roles, suggesting that the issue is operationally familiar across multiple parts of the safety workflow.

What Makes a Narrative Inspection-Ready?

In this article, we use the term “inspection-ready” as a practical descriptor rather than a formal regulatory designation. We use it to describe narratives that are complete, clinically coherent, internally consistent, and able to support reviewer understanding during inspection, audit, or routine oversight. While no single global guideline prescribes a specific narrative format, expectations for clear, consistent, clinically interpretable case documentation are reflected across major pharmacovigilance frameworks. In this exploratory survey, respondents represented professionals working in organizations operating primarily within the US, EU, and globally aligned pharmacovigilance environments.

Across this exploratory sample, four practical characteristics consistently emerged as markers of a stronger, more defensible narrative:

• Clear clinical reasoning: The narrative explains how the company reached its safety assessment, including relevant context and confounders.
• Logical chronology: Events are presented in a sequence that is easy to follow.
• Alignment with case data: The narrative remains consistent with structured data and coded information.
• Continuity across follow-ups: Updates preserve the integrity of the case story over time.

Together, these elements suggest that a defensible narrative is not merely complete; it can stand on its own when reviewed by someone outside the day-to-day workflow.

At a high level, this framing is broadly consistent with expectations reflected under major regulatory standards including:

• EMA Good Pharmacovigilance Practices (GVP) Module VI—Collection, management and submission of reports of suspected adverse reactions (focus on quality and completeness of case narratives): https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf
• ICH E2A—Clinical safety data management: Definitions and standards for expedited reporting (clinical trials): https://database.ich.org/sites/default/files/E2A_Guideline.pdf
• ICH E2D—Post-approval safety data management: Definitions and standards for expedited reporting (post-marketing): https://database.ich.org/sites/default/files/E2D_Guideline.pdf
• FDA Guidance on Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment (main page): https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment

Narrative Variability Is Common, Even in Similar Cases

The most consistent observation from respondents was that narratives for similar cases can vary significantly in structure, causality language, and clinical framing. This does not necessarily mean the cases are noncompliant. However, it does raise a practical concern: When the same type of case is described in materially different ways, the logic behind the company’s safety assessment may be harder to follow.

In the survey, most respondents reported inconsistent narrative styles across similar cases. This suggests that variability is not an isolated issue. In many organizations, it is an expected byproduct of complex workflows, multiple contributors, and evolving case information.

For example, consider a patient who initiated study drug (Drug X) and developed nausea and vomiting three days later, leading to study drug discontinuation with subsequent symptom resolution. The event was assessed as possibly related based on the temporal relationship.

Narrative A:

The patient initiated Drug X and developed nausea and vomiting three days later. Due to these events, Drug X was discontinued. Following discontinuation, the patient’s symptoms resolved. Based on temporal association and lack of alternative causes, the event was assessed as possibly related to Drug X.

Narrative B:

The patient experienced nausea and vomiting, which resolved after discontinuation of Drug X. The patient had initiated treatment prior to the event. The event was assessed as possibly related.

While both narratives contain the same core information, Narrative A presents a clear sequence of events and clinical reasoning, whereas Narrative B requires the reviewer to reconstruct the timeline and infer how the conclusion was reached.

For inspectors, auditors, or internal reviewers, that variability can create friction. A technically complete case may still require extra effort to understand if the narrative does not clearly and consistently communicate the patient story and the rationale for the company’s conclusion.

QC Often Confirms Completeness, Not Always Clinical Clarity

Another recurring theme was the difference between technical completeness and clear clinical logic.

Respondents described QC processes as generally strong in verifying whether required narrative elements are present. These checks often include:

• Required components of the narrative
• Logical chronology of events
• Template adherence
• Alignment with structured case data and coding

These controls are essential. In the survey, a majority of respondents indicated that QC tends to focus primarily on technical details.

But respondents also pointed to a gap: The reasoning behind the narrative is not always assessed with the same level of structure. A narrative may be complete, chronologically correct, and aligned with coded data, yet still fail to clearly explain how the safety assessment was reached.

This distinction matters, as this gap can have downstream consequences. Unclear clinical reasoning in the narrative may complicate medical review, hinder consistent signal evaluation across multiple cases, and weaken the company’s ability to defend its safety conclusions during regulatory inspections or audits. It may also lead to inconsistent interpretation of similar cases, increased reviewer burden, and the need for additional clarification or rework during the review process.

During inspection, reviewers are not only checking whether required fields are present. They are also evaluating whether the narrative presents a coherent and transparent account of the case.

Workflow Handoffs Are a Major Source of Narrative Divergence

Respondents consistently identified workflow transitions as the points where narratives are most likely to drift.

In modern pharmacovigilance operations, a single case may move across intake, case processing, narrative development, QC, and medical review. Each handoff can introduce subtle shifts in emphasis, wording, or clinical interpretation. This dynamic is increasingly common in modern pharmacovigilance operations, where outsourced partnerships, distributed teams, and multivendor workflows create more handoff points across the case lifecycle and increase the risk of narrative drift unless consistency is actively maintained.

The survey highlighted several common pressure points:

• Multiple writers may organize the same case differently
• Follow-up information may be integrated inconsistently across versions
• Medical review may change causality language late in the workflow
• Operational handoffs can alter how the patient story is framed

In the survey, nearly all respondents identified workflow handoffs as a key source of narrative divergence, and many respondents reported rework during review. These findings reinforce a broader operational truth: Narrative inconsistency often reflects workflow complexity, not simply writing quality.

This is an important distinction. If teams treat narrative variability as an isolated documentation problem, they may miss the upstream process issues that are driving it.

Why This Matters Now

The challenge is becoming more important, not less.

In many modern pharmacovigilance operations, case review and narrative development occur across distributed teams, external vendor partnerships, flexible resourcing models, and layered review structures. These approaches can improve scalability and throughput, but they can also increase the number of handoff points where narrative inconsistency can enter the process.

As a result, teams may believe they are controlling quality because required elements, chronology, and coding are being checked, while the underlying clinical logic remains inconsistently expressed. This can contribute to inspection observations, delayed or inconsistent signal assessment, increased clarification during review, and greater burden on reviewers. Over time, that gap can lead to avoidable rework, reviewer friction, and narratives that are harder to defend during inspections or audits.

The takeaway is practical: Narrative quality is not only a writing issue. It is a workflow design issue.

What Safety Teams Can Do Next

Based on these observations, pharmacovigilance teams would benefit from focusing on three areas:

1. Standardize expectations beyond templates. Templates support consistency, but teams also need shared expectations for how clinical reasoning, safety conclusions, and follow-up continuity should be documented, so similar cases are presented and interpreted consistently across contributors.
2. Expand QC beyond technical completeness. QC should continue to verify required elements, but teams may also benefit from a more explicit approach to evaluating whether the narrative clearly explains the safety assessment, allowing reviewers to understand and trust the clinical reasoning without additional clarification.
3. Reduce handoff risk across the case lifecycle. If multiple functions contribute to the same case, organizations should define how the narrative framework is preserved as the case moves between processing, review, and medical assessment, helping maintain continuity and reduce variability introduced during workflow transitions.

Industry groups such as the International Council for Harmonisation (ICH), the Council for International Organizations of Medical Sciences (CIOMS), and professional associations such as the Drug Information Association (DIA) continue to explore best practices in pharmacovigilance quality, case documentation, and consistency. These organizations continue to provide important resources and forums for ongoing discussion and development in the pharmacovigilance area.

A Practical Takeaway

This exploratory industry pulse is not intended to represent the entire pharmacovigilance landscape, but it does reinforce a familiar operational reality: Technically complete narratives are not always inspection-ready narratives. A technically complete narrative may satisfy required fields, templates, and data alignment checks, while an inspection-ready narrative clearly tells the clinical story in a way that allows reviewers to quickly understand the case, interpret the company’s safety conclusions, and assess them as clinically and regulatorily defensible.

As pharmacovigilance workflows continue to evolve, safety leadership, pharmacovigilance operations, and quality functions should take ownership of treating narrative consistency as a cross-functional quality objective, not simply a downstream writing task. In the near term, that means looking beyond template compliance and asking a more practical question: Can the narrative stand on its own when it matters most?